by Startups in the biotech and life science industry frequently drive the numbers. In this post, we share ten of the top. However, let’s back up and review the biotech industry as a whole. In short, biotech uses life forms to help solve problems through technology.
Biotechnology consists of three main branches: medical, agricultural, and industrial—often referred to as “red, green, and white,” respectively.
The medical branch and include:
1. Pharmaceuticals:
This biotech subcategory focuses on discovering, developing, and monitoring medication to benefit people’s health. And, pharmaceutical medicine consists of clinical testing and trials, drug research, and safety profiles of specific medications.
2. Therapeutics:
Therapeutics work toward the treatment of diseases, focusing mainly on the science of healing. Furthermore, this biotech subcategory deals primarily with how the drugs are used as well as drug administration in terms of disease treatment.
3. Cerevel Therapeutics
Bain Capital and Pfizer launched Cerevel Therapeutics to develop drugs for central nervous system (CNS) disorders, such as Parkinson’s Disease, Alzheimer’s, and epilepsy.
Besides, Cerevel began a Phase I clinical trial for psychosis and two separate Phase II clinical trials for Parkinson’s and also epilepsy. Its epilepsy trial produced encouraging results involving the drug lorazepam.
4. Century Therapeutics
Century Therapeutics develops iPSC-derived immune effector therapy, or otherwise known as “off-the-shelf” therapy, for cancer treatment. And, this company’s goal is to overcome the limitations of first-generation cell therapy.
5. Anthos Therapeutics
Anthos prides itself on developing and commercializing life-preserving therapies. Its primary asset is MAA868, which is an antibody currently in Phase II development. And, helping high-risk cardiovascular patients is the goal of this startup.
6. Cyclerion Therapeutics
The company’s goal is to address a broad range of serious and orphan diseases, such as sickle cell disease and diabetic nephropathy. Furthermore, also, IW-6463 is in Phase I for serious and orphan CNS disease, and two programs targeting liver and lung diseases are in late-stage discovery programs.
7. Mirum Pharmaceuticals
Mirum Pharmaceuticals is creativing transformative medicine for rare liver disease, such as Alagille syndrome (ALGS) and progressive familial intrahepatic cholestasis (PFIC). For both diseases mentioned, Mirum reported positive Phase II data in April 2019. In July 2019, it launched a Phase III trial of the PFIC-focused drug.
8. Maze Therapeutics
Third Rock Ventures, ARCH Venture Partners, Google Ventures, Foresite Capital, Casdin Capital, Alexandria Venture Investments. Maze aims to “decode the mysteries of genetic modifiers in a range of severe diseases.” By using advanced algorithms and data science, Maze studies natural human genetic variation.
0 comments: